On September 23, 2019 Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), reported that an abstract from its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of AG013 in severe oral mucositis, will be presented as a poster at the upcoming European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress ("ESMO") on September 27 – October 1, 2019, in Barcelona, Spain (Press release, Oragenics, SEP 23, 2019, View Source [SID1234539711]),.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled "Severe Oral Mucositis Mitigation by Genetically Modified Lactococcus Lactis Bacteria (LLB) Producing Human Trefoil Factor 1 (hTFF1; AG013) In Patients Being Treated with Concomitant Chemoradiation (CRT) for Oral and Oralpharyngeal Cancers (OCOCPC)," can be viewed at www.oragenics.com and will be presented at the ESMO (Free ESMO Whitepaper) Congress on September 30, 2019.